Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.
|23/01/2014||02/03/2014||Full Pharmacoeconomic Evaluation Recommended|
|23/05/2014||05/09/2014||Reimbursement not recommended|
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
The HSE has approved reimbursement following confidential price negotiations.